Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Capital Leases (2023 - 2025)

bioAffinity Technologies (BIAF) has disclosed Capital Leases for 3 consecutive years, with $1998.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Leases fell 99.63% to $1998.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1998.0, a 99.63% decrease, with the full-year FY2024 number at $444448.0, down 46.8% from a year prior.
  • Capital Leases was $1998.0 for Q3 2025 at bioAffinity Technologies, down from $3942.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $929570.0 in Q3 2023 to a low of $1998.0 in Q3 2025.
  • A 3-year average of $497263.9 and a median of $543007.0 in 2024 define the central range for Capital Leases.
  • Peak YoY movement for Capital Leases: crashed 41.59% in 2024, then plummeted 99.63% in 2025.
  • bioAffinity Technologies' Capital Leases stood at $835467.0 in 2023, then plummeted by 46.8% to $444448.0 in 2024, then crashed by 99.55% to $1998.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Capital Leases are $1998.0 (Q3 2025), $3942.0 (Q2 2025), and $335899.0 (Q1 2025).